{"protocolSection":{"identificationModule":{"nctId":"NCT01880528","orgStudyIdInfo":{"id":"MC1221"},"secondaryIdInfos":[{"id":"NCI-2013-01139","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"12-008062"},{"id":"P30CA015083","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P30CA015083"}],"organization":{"fullName":"Mayo Clinic","class":"OTHER"},"briefTitle":"Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer","officialTitle":"A Double-Blind Pilot Study to Measure the Effect of Lisinopril vs. Placebo on Pulmonary Distress in Patients Receiving External Beam Radiotherapy to the Lung"},"statusModule":{"statusVerifiedDate":"2019-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-05-31","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2013-06-05","type":"ACTUAL"},"completionDateStruct":{"date":"2019-01-29","type":"ACTUAL"},"studyFirstSubmitDate":"2013-06-15","studyFirstSubmitQcDate":"2013-06-18","studyFirstPostDateStruct":{"date":"2013-06-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-08-28","resultsFirstSubmitQcDate":"2019-08-28","resultsFirstPostDateStruct":{"date":"2019-09-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-12-23","lastUpdatePostDateStruct":{"date":"2020-01-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Mayo Clinic","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This pilot clinical trial studies lisinopril in reducing shortness of breath caused by radiation therapy in patients with lung cancer. Lisinopril may decrease the side effects caused by radiation therapy in patients with lung cancer.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To explore the adverse event profile of lisinopril, during and after external beam radiation therapy (RT) to the lung.\n\nSECONDARY OBJECTIVES:\n\nI. To explore the level of patient-reported acute respiratory distress (dyspnea) during and after external beam RT.\n\nII. To explore the level of patient-reported symptoms during and after external beam RT.\n\nIII. To explore the impact of lisinopril treatment on patient quality of life (QOL) during and after external beam RT.\n\nOUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\nARM I: Beginning within 7 days of beginning radiation therapy, patients receive lisinopril orally (PO) once daily (QD) on days 1-7.\n\nARM II: Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD on days 1-7.\n\nIn both arms, treatment repeats every 7 days for until 3 months after completion of radiation therapy in the absence of disease progression or unacceptable toxicity."},"conditionsModule":{"conditions":["Dyspnea","Non-small Cell Lung Cancer","Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"SUPPORTIVE_CARE","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":23,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm I (lisinopril)","type":"EXPERIMENTAL","description":"Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD on days 1-7.","interventionNames":["Drug: lisinopril"]},{"label":"Arm II (placebo)","type":"PLACEBO_COMPARATOR","description":"Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD on days 1-7.","interventionNames":["Drug: placebo"]}],"interventions":[{"type":"DRUG","name":"lisinopril","description":"Given PO","armGroupLabels":["Arm I (lisinopril)"],"otherNames":["Prinivil","Zestril"]},{"type":"DRUG","name":"placebo","description":"Given PO","armGroupLabels":["Arm II (placebo)"],"otherNames":["PLCB"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Grade 3 or Higher Hypotension, Acute Kidney Injury, Allergic Reaction, or Anaphylaxis, as Measured Using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0","description":"Incidence of grade 3 or higher hypotension, acute kidney injury, allergic reaction, or anaphylaxis, as measured using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. Descriptive statistics of frequency (percentage) will be used to summarize adverse event (AE) incidence and severity in the lisinopril and placebo arms separately.","timeFrame":"Up to 3 months post-radiation therapy"}],"secondaryOutcomes":[{"measure":"Acute Respiratory Distress (Dyspnea), Measured Using of the Maximum Score, at Any Time, of the Shortness of Breath Question (Item #4) on the LCSS (Worst Dyspnea Score)","description":"Acute respiratory distress (dyspnea), measured using of the maximum score, at any time, of the shortness of breath question (Item #4 \"How much shortness of breath do you have?\") on the Lung Cancer Symptom Scale (LCSS) (Worst Dyspnea Score). The LCSS tool contains 6 major symptoms associated with lung malignancies and their effect on overall symptomatic distress, functional activities, and global quality of life (QOL). The item scale ranges from 0-10 (0 = None; 10 = As much as it could be) where the LCSS scoring algorithm is applied to convert to a 0-100 point scale where 100 is best quality of life (QOL), for comparability. Patient scores range from 0 to 100, where 100 was best QOL (i.e. less pulmonary distress).","timeFrame":"Up to 3 months post-radiation therapy"},{"measure":"Experience Shortness of Breath During Exercise as Measured Using Item #3 on the Symptom Experience Questionnaire (SEQ) at Week 4","description":"Experience shortness of breath during exercise as measured using Item #3 (\"Over the past week, did you experience shortness of breath when you exercise or exert yourself?\") on the Symptom Experience Questionnaire (SEQ) at Baseline. The item scale ranges from 0-10 (0 = Not at all; 10 = As bad as it can be) where the SEQ scoring algorithm is applied to convert to a 0-100 point scale where 100 is best quality of life (QOL), for comparability.","timeFrame":"At Week 4"},{"measure":"Quality of Life (Dyspnea When Climbing Stairs) Assessed Using Item #5 of the European Organization for Research on the Treatment of Cancer Lung Cancer Module Survey (EORTC-QLQ-LC13) at Week 4","description":"Dyspnea when climbing as measured using item #5 (\"Were you short of breath when you climbed stairs?\") of the EORTC-QLQ-LC13 at Week 4. The item scale ranges from 1-4 (1 = Not at all; 4 = Very Much) where the EORTC-QLQ-LC13 scoring algorithm is applied to convert to a 0-100 point scale where 100 is best quality of life (QOL), for comparability.","timeFrame":"At Week 4"},{"measure":"Total LCSS Score as Measure by the Lung Cancer Symptom Scale (LCSS) at Week 4","description":"Total LCSS score as measured using the Lung Cancer Symptom Scale (LCSS) at Week 4. The item scale ranges from 0-10 (0 = None; 10 = As much as it could be) where the LCSS scoring algorithm is applied to convert to a 0-100 point scale where 100 is best quality of life (QOL), for comparability.","timeFrame":"At Week 4"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histological confirmation of small cell and non-small cell carcinoma of the lung receiving thoracic radiotherapy \\> 45 Gy, with volume of lung receiving 20 Gy or more (V20Gy) \\>= 20%\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2\n* Absolute neutrophil count (ANC) \\>= 1500/mm\\^3\n* Platelet count \\>= 100,000/mm\\^3\n* Hemoglobin \\> 9.0 g/dL\n* Creatinine clearance \\>= 30 mL/min as calculated using actual body weight and Cockroft Gault formula\n* Initial physical exam with systolic blood pressure (BP) of \\> 100 mmHg and diastolic BP of \\> 60 mmHg\n* Potassium within institutional normal limits\n* Sodium within institutional normal limits\n* Negative pregnancy test done =\\< 14 days prior to registration, for women of childbearing potential only\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Provide informed written consent\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* Willing to provide blood samples for correlative research purposes\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Other active malignancy =\\< 3 years prior to registration; EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment (e.g., maintenance or adjuvant chemotherapy or hormonal therapy) for their cancer\n* History of myocardial infarction =\\< 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias\n* History of prior radiation therapy treatment to the lungs or thorax\n* Existing contraindications to angiotensin-converting enzyme (ACE) inhibitors such as hypersensitivity to ACE inhibitors, bilateral renal artery stenosis, angioedema, or previously documented adverse drug reaction to ACE inhibitors\n* Any of the following:\n\n  * Pregnant women\n  * Nursing women\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception\n* Use of ACE inhibitors (including lisinopril) or ACE receptor blockers (ARB) of any kind =\\< 90 days prior to registration","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Robert Miller, M.D.","affiliation":"Mayo Clinic","role":"STUDY_CHAIR"}],"locations":[{"facility":"Mayo Clinic in Arizona","city":"Scottsdale","state":"Arizona","zip":"85259","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"Mayo Clinic","city":"Rochester","state":"Minnesota","zip":"55905","country":"United States","geoPoint":{"lat":44.02163,"lon":-92.4699}},{"facility":"University of Nebraska Medical Center","city":"Omaha","state":"Nebraska","zip":"68198","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Arm I (Lisinopril)","description":"Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD."},{"id":"FG001","title":"Arm II (Placebo)","description":"Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"COMPLETED","comment":"Evaluable for primary endpoint","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Arm I (Lisinopril)","description":"Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD."},{"id":"BG001","title":"Arm II (Placebo)","description":"Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.0","lowerLimit":"49.0","upperLimit":"87.0"},{"groupId":"BG001","value":"62.0","lowerLimit":"54.0","upperLimit":"83.0"},{"groupId":"BG002","value":"62.0","lowerLimit":"49.0","upperLimit":"87.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Grade 3 or Higher Hypotension, Acute Kidney Injury, Allergic Reaction, or Anaphylaxis, as Measured Using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0","description":"Incidence of grade 3 or higher hypotension, acute kidney injury, allergic reaction, or anaphylaxis, as measured using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. Descriptive statistics of frequency (percentage) will be used to summarize adverse event (AE) incidence and severity in the lisinopril and placebo arms separately.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of patients","timeFrame":"Up to 3 months post-radiation therapy","groups":[{"id":"OG000","title":"Arm I (Lisinopril)","description":"Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD."},{"id":"OG001","title":"Arm II (Placebo)","description":"Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Acute Respiratory Distress (Dyspnea), Measured Using of the Maximum Score, at Any Time, of the Shortness of Breath Question (Item #4) on the LCSS (Worst Dyspnea Score)","description":"Acute respiratory distress (dyspnea), measured using of the maximum score, at any time, of the shortness of breath question (Item #4 \"How much shortness of breath do you have?\") on the Lung Cancer Symptom Scale (LCSS) (Worst Dyspnea Score). The LCSS tool contains 6 major symptoms associated with lung malignancies and their effect on overall symptomatic distress, functional activities, and global quality of life (QOL). The item scale ranges from 0-10 (0 = None; 10 = As much as it could be) where the LCSS scoring algorithm is applied to convert to a 0-100 point scale where 100 is best quality of life (QOL), for comparability. Patient scores range from 0 to 100, where 100 was best QOL (i.e. less pulmonary distress).","populationDescription":"Patients who completed the LCSS Item #4 at any time during the study are included in this analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Up to 3 months post-radiation therapy","groups":[{"id":"OG000","title":"Arm I (Lisinopril)","description":"Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD."},{"id":"OG001","title":"Arm II (Placebo)","description":"Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":"23.8"},{"groupId":"OG001","value":"42.0","spread":"27.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.006","statisticalMethod":"Kruskal-Wallis"}]},{"type":"SECONDARY","title":"Experience Shortness of Breath During Exercise as Measured Using Item #3 on the Symptom Experience Questionnaire (SEQ) at Week 4","description":"Experience shortness of breath during exercise as measured using Item #3 (\"Over the past week, did you experience shortness of breath when you exercise or exert yourself?\") on the Symptom Experience Questionnaire (SEQ) at Baseline. The item scale ranges from 0-10 (0 = Not at all; 10 = As bad as it can be) where the SEQ scoring algorithm is applied to convert to a 0-100 point scale where 100 is best quality of life (QOL), for comparability.","populationDescription":"Patients who completed Item #3 on the SEQ at week 4 are included in this analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"At Week 4","groups":[{"id":"OG000","title":"Arm I (Lisinopril)","description":"Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD."},{"id":"OG001","title":"Arm II (Placebo)","description":"Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":"0"},{"groupId":"OG001","value":"68.6","spread":"27.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0337","statisticalMethod":"Kruskal-Wallis"}]},{"type":"SECONDARY","title":"Quality of Life (Dyspnea When Climbing Stairs) Assessed Using Item #5 of the European Organization for Research on the Treatment of Cancer Lung Cancer Module Survey (EORTC-QLQ-LC13) at Week 4","description":"Dyspnea when climbing as measured using item #5 (\"Were you short of breath when you climbed stairs?\") of the EORTC-QLQ-LC13 at Week 4. The item scale ranges from 1-4 (1 = Not at all; 4 = Very Much) where the EORTC-QLQ-LC13 scoring algorithm is applied to convert to a 0-100 point scale where 100 is best quality of life (QOL), for comparability.","populationDescription":"Patients who completed item #5 on the EORTC-QLQ-LC13 at week 4 are included in this analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"At Week 4","groups":[{"id":"OG000","title":"Arm I (Lisinopril)","description":"Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD."},{"id":"OG001","title":"Arm II (Placebo)","description":"Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":"17.8"},{"groupId":"OG001","value":"51.9","spread":"33.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0427","statisticalMethod":"Kruskal-Wallis"}]},{"type":"SECONDARY","title":"Total LCSS Score as Measure by the Lung Cancer Symptom Scale (LCSS) at Week 4","description":"Total LCSS score as measured using the Lung Cancer Symptom Scale (LCSS) at Week 4. The item scale ranges from 0-10 (0 = None; 10 = As much as it could be) where the LCSS scoring algorithm is applied to convert to a 0-100 point scale where 100 is best quality of life (QOL), for comparability.","populationDescription":"Patients who completed the LCSS at week 4 are included in this analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"At Week 4","groups":[{"id":"OG000","title":"Arm I (Lisinopril)","description":"Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD."},{"id":"OG001","title":"Arm II (Placebo)","description":"Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.8","spread":"11.2"},{"groupId":"OG001","value":"66.5","spread":"17.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0237","statisticalMethod":"Kruskal-Wallis"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Up to 3 months post-radiation therapy","description":"Each CTCAE term is a representation of a specific event used for medical documentation \\& analysis \\& is a single MedDRA Lowest Level Term (LLT). All graded AEs are reported for patients assessed for AEs and completed AE form. Serious AE (SAE) reports may include any secondary serious or non-serious events considered related to the primary event (the reason for filing an expedited report); collectively, these events are referred to as Expedited AEs, \\& appear in the SAE table.","eventGroups":[{"id":"EG000","title":"Arm I (Lisinopril)","description":"Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":4,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG001","title":"Arm II (Placebo)","description":"Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":1,"seriousNumAtRisk":10,"otherNumAffected":10,"otherNumAtRisk":10}],"seriousEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":2,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"White blood cell decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Hematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]}],"otherEvents":[{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Esophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"White blood cell decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":9,"numAtRisk":12},{"groupId":"EG001","numEvents":32,"numAffected":9,"numAtRisk":10}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":12},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":10}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Terence T Sio, MD, MS","organization":"Mayo Clinic","email":"Sio.Terence@mayo.edu","phone":"480/301-7050"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D004417","term":"Dyspnea"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D055752","term":"Small Cell Lung Carcinoma"}],"ancestors":[{"id":"D012120","term":"Respiration Disorders"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D012818","term":"Signs and Symptoms, Respiratory"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D017706","term":"Lisinopril"}],"ancestors":[{"id":"D004151","term":"Dipeptides"},{"id":"D009842","term":"Oligopeptides"},{"id":"D010455","term":"Peptides"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"}]}},"hasResults":true}